<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37402261</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1853-0605</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>31</Day></PubDate></JournalIssue><Title>Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)</Title><ISOAbbreviation>Rev Fac Cien Med Univ Nac Cordoba</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>36</StartPage><EndPage>42</EndPage><MedlinePgn>36-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.31053/1853.0605.v80.n1.36817</ELocationID><Abstract><AbstractText>MINOCA es un s&#xed;ndrome que abarca varias patolog&#xed;as y que ocurre en el contexto cl&#xed;nico de un S&#xed;ndrome Coronario Agudo. Su incidencia var&#xed;a de acuerdo con la poblaci&#xf3;n estudiada, m&#xe9;todos de diagn&#xf3;sticos utilizados y si han incluido a la Miocarditis y S&#xed;ndrome de Takotsubo, los cu&#xe1;les, fueron excluidos recientemente de la definici&#xf3;n de MINOCA. Por esta raz&#xf3;n, consideramos que la novedad de esta publicaci&#xf3;n es la no inclusi&#xf3;n de estas dos patolog&#xed;as y, por lo tanto, el objetivo de la presente revisi&#xf3;n es actualizar este s&#xed;ndrome de forma concisa. Tambi&#xe9;n se aborda el manejo de los tres tipos de MINOCA, cuyo diagn&#xf3;stico se basa fundamentalmente en la utilizaci&#xf3;n de im&#xe1;genes complementarias espec&#xed;ficas, ya que la coronariografia tiene sus limitaciones. El tratamiento ser&#xe1; en general farmacol&#xf3;gico de acuerdo con el mecanismo fisiopatol&#xf3;gico involucrado.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ricarte-Bratti</LastName><ForeName>Juan Pablo</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Universidad Nacional de C&#xf3;rdoba. jpricartebratti@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bono</LastName><ForeName>Julio Oscar Emilio</ForeName><Initials>JOE</Initials><AffiliationInfo><Affiliation>Sanatorio Allende. jbonomd@sanatorioallende.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barcudi</LastName><ForeName>Raul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>. raulbarcudi@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Fisiopatolog&#xed;a y algoritmo diagn&#xf3;stico y terap&#xe9;utico del MINOCA.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Rev Fac Cien Med Univ Nac Cordoba</MedlineTA><NlmUniqueID>8303003</NlmUniqueID><ISSNLinking>0014-6722</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000088442" MajorTopicYN="Y">MINOCA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>4</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>4</Day><Hour>15</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37402261</ArticleId><ArticleId IdType="doi">10.31053/1853.0605.v80.n1.36817</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32496331</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Population-Based Analysis of Adherence to Postdischarge Extended Venous Thromboembolism Prophylaxis After Colorectal Resection.</ArticleTitle><Pagination><StartPage>911</StartPage><EndPage>917</EndPage><MedlinePgn>911-917</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001650</ELocationID><Abstract><AbstractText Label="BACKGROUND">Prevention of venous thromboembolism after colorectal surgery remains challenging. National guidelines endorse thromboembolism prophylaxis for 4 weeks after colorectal cancer resection. Expert consensus favors extended prophylaxis after IBD surgery. The actual frequency of prescription after resection remains unknown.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to assess prescription of extended, postdischarge venous thromboembolism prophylaxis after resection in Michigan.</AbstractText><AbstractText Label="DESIGN">This is a retrospective review of elective colorectal resections within a statewide collaborative receiving postdischarge, extended-duration prophylaxis.</AbstractText><AbstractText Label="SETTING">This study was conducted between October 2015 and February 2018 at an academic center.</AbstractText><AbstractText Label="PATIENTS">A total of 5722 patients (2171 with colorectal cancer, 266 with IBD, and 3285 with other).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">We compared the prescription of extended, postdischarge prophylaxis over time, between hospitals and by indication.</AbstractText><AbstractText Label="RESULTS">Of 5722 patients, 373 (6.5%) received extended-duration prophylaxis after discharge. Use was similar between patients undergoing surgery for cancer (282/2171, 13.0%) or IBD (31/266, 11.7%, p = 0.54), but was significantly more common for both patients undergoing surgery for cancer or IBD in comparison with patients with other indications (60/3285, 1.8%, p &lt; 0.001). Use increased significantly among patients with cancer (6.8%-16.8%, p &lt; 0.001) and patients with IBD (0%-15.1%, p &lt; 0.05) over the study period. For patients with other diagnoses, use was rare and did not vary significantly (1.5%-2.3%, p = 0.49). Academic centers and large hospitals (&gt;300 beds) were significantly more likely to prescribe extended-duration prophylaxis for all conditions (both p &lt; 0.001), with the majority of prophylaxis concentrated at only a few hospitals.</AbstractText><AbstractText Label="LIMITATIONS">This study was limited by the lack of assessment of actual adherence, small number of observed venous thromboembolism events, small sample of patients with IBD, and restriction to the state of Michigan.</AbstractText><AbstractText Label="CONCLUSIONS">The use of extended-duration venous thromboembolism prophylaxis after discharge is increasing, but remains uncommon in most hospitals. Efforts to improve adherence may require quality implementation initiatives or targeted payment incentives. See Video Abstract at http://links.lww.com/DCR/B193. AN&#xc1;LISIS POBLACIONAL DE LA ADHERENCIA A LA PROFILAXIS ANTI-TROMB&#xd3;TICA EXTENDIDA (TEV) EN PACIENTES DE ALTA LUEGO DE UNA RESECCI&#xd3;N COLORECTAL.: La prevenci&#xf3;n del tromboembolismo venoso despu&#xe9;s de cirug&#xed;a colorrectal sigue siendo un desaf&#xed;o. Las gu&#xed;as nacionales han aprobado la profilaxia del tromboembolismo durante cuatro semanas luego de una resecci&#xf3;n de c&#xe1;ncer colorrectal. El consenso de expertos favorece la profilaxia extendida solamente despu&#xe9;s de la cirug&#xed;a por enfermedad inflamatoria intestinal. La frecuencia real de prescripci&#xf3;n despu&#xe9;s de la resecci&#xf3;n colorrectal sigue siendo desconocida.Evaluar la prescripci&#xf3;n de profilaxia prolongada de tromboembolismo venoso despu&#xe9;s del alta luego de una resecci&#xf3;n colorrectal en Michigan.Revisi&#xf3;n retrospectiva de las resecciones colorrectales electivas seguidas de una profilaxia de larga duraci&#xf3;n con el apoyo de todo el estado (MI).Este estudio se realiz&#xf3; entre octubre de 2015 y febrero de 2018 en un solo centro acad&#xe9;mico.Un universo de 5722 pacientes operados (2171 por c&#xe1;ncer colorrectal, 266 por enfermedad inflamatoria intestinal, 3285 por otros diagn&#xf3;sticos).Se compar&#xf3; la prescripci&#xf3;n de profilaxia prolongada despu&#xe9;s del alta seg&#xfa;n la duraci&#xf3;n, los hospitales y la indicaci&#xf3;n.De 5722 pacientes, 373 (6.5%) recibieron profilaxia de duraci&#xf3;n prolongada despu&#xe9;s del alta. El uso fue similar entre pacientes sometidos a cirug&#xed;a por c&#xe1;ncer (282/2171, 13.0%) o enfermedad inflamatoria intestinal (31/266, 11.7%, p = 0.54), pero fue significativamente m&#xe1;s com&#xfa;n para ambos en comparaci&#xf3;n con pacientes con otras indicaciones (60/3285, 1.8%, p &lt; 0.001). El uso aument&#xf3; significativamente entre pacientes con c&#xe1;ncer (6.8% a 16.8% (p &lt; 0.001)) y en pacientes con enfermedad inflamatoria intestinal (0% a 15.1%, p &lt; 0.05) durante el per&#xed;odo de estudio. Para pacientes con otros diagn&#xf3;sticos, su utilizaci&#xf3;n fue rara y no vari&#xf3; significativamente (1.5% a 2.3%, p = 0.49). Los centros acad&#xe9;micos y los grandes hospitales (&gt;300 camas) ten&#xed;an mayor probabilidad de prescribir la profilaxia de duraci&#xf3;n extendida en todas las afecciones (ambas p &lt; 0.001), pero la mayor&#xed;a de las profilaxis se concentraron el algunos pocos grandes hospitales.Este estudio estuvo limitado por la falta de evaluaci&#xf3;n de actuales adherentes, por el peque&#xf1;o n&#xfa;mero de eventos tromboemb&#xf3;licos venosos observados, por la peque&#xf1;a muestra de pacientes con enfermedad inflamatoria intestinal y debido a ciertas restricciones en el estado de Michigan.El uso de profilaxia para el tromboembolismo venoso de duraci&#xf3;n prolongada despu&#xe9;s del alta est&#xe1; en aumento, pero su uso sigue siendo poco frecuente en la mayor&#xed;a de los hospitales. Los esfuerzos para mejorar la adherencia al tratamiento pueden requerir iniciativas de mejor&#xed;a en la calidad o incentivos espec&#xed;ficos de reembolso. Consulte Video Resumen en http://links.lww.com/DCR/B193. (Traducci&#xf3;n-Dr. Xavier Delgadillo).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mukkamala</LastName><ForeName>Anudeep</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Healthcare Outcomes and Policy (CHOP), University of Michigan Hospitals, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Center for Healthcare Outcomes and Policy (CHOP), University of Michigan Hospitals, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Roo</LastName><ForeName>Ana C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Center for Healthcare Outcomes and Policy (CHOP), University of Michigan Hospitals, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogilvie</LastName><ForeName>James W</ForeName><Initials>JW</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Michigan State University/Spectrum Health, Grand Rapids, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regenbogen</LastName><ForeName>Scott E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Center for Healthcare Outcomes and Policy (CHOP), University of Michigan Hospitals, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AG047252</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D057405">Webcast</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003107" MajorTopicYN="N">Colorectal Surgery</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017558" MajorTopicYN="N">Elective Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008824" MajorTopicYN="N" Type="Geographic">Michigan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055656" MajorTopicYN="N">Prescriptions</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES:">La prevenci&#xf3;n del tromboembolismo venoso despu&#xe9;s de cirug&#xed;a colorrectal sigue siendo undesaf&#xed;o. Las gu&#xed;as nacionales han aprobado la profilaxia del tromboembolismo durante cuatro semanas luego de una resecci&#xf3;n de c&#xe1;ncer colorrectal. El consenso de expertos favorece la profilaxia extendida solamente despu&#xe9;s de la cirug&#xed;a por enfermedad inflamatoria intestinal. La frecuencia real de prescripci&#xf3;n despu&#xe9;s de la resecci&#xf3;n colorrectal sigue siendo desconocida.</AbstractText><AbstractText Label="OBJETIVO:">Evaluar la prescripci&#xf3;n de profilaxia prolongada de tromboembolismo venoso despu&#xe9;s del alta luego de una resecci&#xf3;n colorrectal en Michigan.</AbstractText><AbstractText Label="DISE&#xd1;O:">Revisi&#xf3;n retrospectiva de las resecciones colorrectales electivas seguidas de una profilaxia de larga duraci&#xf3;n con el apoyo de todo el estado (MI).</AbstractText><AbstractText Label="AJUSTE:">Este estudio se realiz&#xf3; entre octubre de 2015 y febrero de 2018 en un solo centro acad&#xe9;mico.</AbstractText><AbstractText Label="PACIENTES:">Un universo de 5722 pacientes operados (2171 por c&#xe1;ncer colorrectal, 266 por enfermedad inflamatoria intestinal, 3285 por otros diagn&#xf3;sticos).</AbstractText><AbstractText Label="PRINCIPALES RESULTADOS:">Se compar&#xf3; la prescripci&#xf3;n de profilaxia prolongada despu&#xe9;s del alta seg&#xfa;n la duraci&#xf3;n, los hospitales y la indicaci&#xf3;n.</AbstractText><AbstractText Label="RESULTADOS:">De 5722 pacientes, 373 (6.5%) recibieron profilaxia de duraci&#xf3;n prolongada despu&#xe9;s del alta. El uso fue similar entre pacientes sometidos a cirug&#xed;a por c&#xe1;ncer (282/2171, 13.0%) o enfermedad inflamatoria intestinal (31/266, 11.7%, <i>p</i> = 0.54), pero fue significativamente m&#xe1;s com&#xfa;n para ambos en comparaci&#xf3;n con pacientes con otras indicaciones (60/3285, 1.8%, <i>p</i> &lt; 0.001). El uso aument&#xf3; significativamente entre pacientes con c&#xe1;ncer (6.8% a 16.8% (<i>p</i> &lt; 0.001)) y en pacientes con enfermedad inflamatoria intestinal (0% a 15.1%, <i>p</i> &lt; 0.05) durante el per&#xed;odo de estudio. Para pacientes con otros diagn&#xf3;sticos, su utilizaci&#xf3;n fue rara y no vari&#xf3; significativamente (1.5% a 2.3%, <i>p</i> = 0.49). Los centros acad&#xe9;micos y los grandes hospitales (&gt;300 camas) ten&#xed;an mayor probabilidad de prescribir la profilaxia de duraci&#xf3;n extendida en todas las afecciones (ambas <i>p</i> &lt; 0.001), pero la mayor&#xed;a de las profilaxis se concentraron el algunos pocos grandes hospitales.</AbstractText><AbstractText Label="LIMITACIONES:">Este estudio estuvo limitado por la falta de evaluaci&#xf3;n de actuales adherentes, por el peque&#xf1;o n&#xfa;mero de eventos tromboemb&#xf3;licos venosos observados, por la peque&#xf1;a muestra de pacientes con enfermedad inflamatoria intestinal y debido a ciertas restricciones en el estado de Michigan.</AbstractText><AbstractText Label="CONCLUSIONES:">El uso de profilaxia para el tromboembolismo venoso de duraci&#xf3;n prolongada despu&#xe9;s del alta est&#xe1; en aumento, pero su uso sigue siendo poco frecuente en la mayor&#xed;a de los hospitales. Los esfuerzos para mejorar la adherencia al tratamiento pueden requerir iniciativas de mejor&#xed;a en la calidad o incentivos espec&#xed;ficos de reembolso. Consulte <b>Video Resumen</b> en http://links.lww.com/DCR/B193. <i>(Traducci&#xf3;n&#x2014;Dr. Xavier Delgadillo)</i></AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32496331</ArticleId><ArticleId IdType="mid">NIHMS1659827</ArticleId><ArticleId IdType="pmc">PMC7804389</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001650</ArticleId><ArticleId IdType="pii">00003453-202007000-00011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ali F, Al-Kindi SG, Blank JJ, Peterson CY, Ludwig KA, Ridolfi TJ. Elevated venous thromboembolism risk following colectomy for IBD is equal to those for colorectal cancer for ninety days after surgery. Dis Colon Rectum. 2018;61:375&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">29420429</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson MZ, Connelly TM, Tinsley A, Hollenbeak CS, Koltun WA, Messaris E. Ulcerative colitis is associated with an increased risk of venous thromboembolism in the postoperative period: the results of a matched cohort analysis. Ann Surg. 2015;261:1160&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">24983992</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e227S&#x2013;e277S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278061</ArticleId><ArticleId IdType="pubmed">22315263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson UO, Scott MJ, Hubner M, et al. Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS&#xae;) Society Recommendations: 2018. World J Surg. 2019;43:659&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">30426190</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl TJ, Gregorcyk SG, Hyman NH, Buie WD; Standards Practice Task Force of The American Society of Colon and Rectal Surgeons. Practice parameters for the prevention of venous thrombosis. Dis Colon Rectum. 2006;49:1477&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">17041751</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasaiah N, Arsalani-Zadeh R, Monson JR. Thrombo-prophylaxis in colorectal surgery: a National Questionnaire Survey of the members of the Association of Coloproctology of Great Britain and Ireland. Colorectal Dis. 2012;14:e390&#x2013;e393.</Citation><ArticleIdList><ArticleId IdType="pubmed">22321914</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkow RP, Bilimoria KY, Sohn MW, et al. Adherence with postdischarge venous thromboembolism chemoprophylaxis recommendations after colorectal cancer surgery among elderly Medicare beneficiaries. Ann Surg. 2014;260:103&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">24169191</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady MT, Patts GJ, Rosen A, et al. Postoperative venous thromboembolism in patients undergoing abdominal surgery for IBD: a common but rarely addressed problem. Dis Colon Rectum. 2017;60:61&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">27926558</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser Family Foundation. Market Share and Enrollment of Largest Three Insurers &#x2013; Large Group Market. www.kff.org/other/state-indicator/market-share-and-enrollment-of-largest-three-insurers-large-group-market/?currentTimeframe=0&amp;selectedRows=%7B%22states%22:%7B%22michigan%22:%7B%7D%7D%7D&amp;sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D.
Accessed
July 3, 2019.</Citation></Reference><Reference><Citation>Nelson DW, Simianu VV, Bastawrous AL, et al.; Colorectal Writing Group for Surgical Care and Outcomes Assessment Program-Comparative Effectiveness Research Translation Network (SCOAP-CERTAIN) Collaborative. Thromboembolic complications and prophylaxis patterns in colorectal surgery. JAMA Surg. 2015;150:712&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545402</ArticleId><ArticleId IdType="pubmed">26060977</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming FJ, Aquina CT. Extended-duration venous thromboembolism prophylaxis following colorectal surgery: ready for prime time? Dis Colon Rectum. 2018;61:273&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">29420420</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown SR, Fearnhead NS, Faiz OD, et al.; ACPGBI IBD Surgery Consensus Collaboration. The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease. Colorectal Dis. 2018;20(suppl 8):3&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">30508274</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanderson B, Hitos K, Fletcher JP. Venous thromboembolism following colorectal surgery for suspected or confirmed malignancy. Thrombosis. 2011;2011:828030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200268</ArticleId><ArticleId IdType="pubmed">22084669</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannuzzi JC, Rickles AS, Kelly KN, et al. Defining high risk: cost-effectiveness of extended-duration thromboprophylaxis following major oncologic abdominal surgery. J Gastrointest Surg. 2014;18:60&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4652588</ArticleId><ArticleId IdType="pubmed">24101450</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaglione L, Piobbici M, Pagano E, Ballini L, Tamponi G, Cic-cone G. Implementing guidelines for venous thromboembolism prophylaxis in a large Italian teaching hospital: lights and shadows. Haematologica. 2005;90:678&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">15921383</ArticleId></ArticleIdList></Reference><Reference><Citation>Caprini JA, Hyers TM. Compliance with antithrombotic guidelines. Manag Care. 2006;15:49&#x2013;50, 53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17036939</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez FJ, Bilbao MS, Saimovici J, Vaccaro C. Improving adherence rate of extended prophylaxis for venous thromboembolic disease after abdominal and pelvic oncologic surgery: a pilot educational study. Clin Appl Thromb Hemost. 2015;21:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">25908111</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu JV, Collins SD, Seese E, et al. Evidence that a regional surgical collaborative can transform care: surgical site infection prevention practices for colectomy in Michigan. J Am Coll Surg. 2018;226:91&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">29111416</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolian VC, Regenbogen SE. Statewide clinic registries: the Michigan Surgical Quality Collaborative. Clin Colon Rectal Surg. 2019;32:16&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327739</ArticleId><ArticleId IdType="pubmed">30647542</ArticleId></ArticleIdList></Reference><Reference><Citation>Share DA, Campbell DA, Birkmeyer N, et al. How a regional collaborative of hospitals and physicians in Michigan cut costs and improved the quality of care. Health Aff (Millwood). 2011;30:636&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">21471484</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30067720</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2444-054X</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>4</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Cirugia y cirujanos</Title><ISOAbbreviation>Cir Cir</ISOAbbreviation></Journal><ArticleTitle>[Manejo quir&#xfa;rgico del divert&#xed;culo de Zenker].</ArticleTitle><Pagination><StartPage>355</StartPage><EndPage>358</EndPage><MedlinePgn>355-358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/CIRU.M18000054</ELocationID><Abstract><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">Los divert&#xed;culos de Zenker son los divert&#xed;culos m&#xe1;s frecuentes del es&#xf3;fago. El tratamiento quir&#xfa;rgico m&#xe1;s utilizado es la diverticulectom&#xed;a con miotom&#xed;a del cricofar&#xed;ngeo abierta. En a&#xf1;os recientes se ha propuesto el tratamiento endosc&#xf3;pico.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Presentar la experiencia en el manejo de esta patolog&#xed;a en un hospital de referencia.</AbstractText><AbstractText Label="M&#xc9;TODO" NlmCategory="UNASSIGNED">Fueron revisados los expedientes de los pacientes intervenidos quir&#xfa;rgicamente por divert&#xed;culo de Zenker en un periodo de 7 a&#xf1;os. Los datos obtenidos incluyeron demogr&#xe1;ficos, cuadro cl&#xed;nico, abordaje diagn&#xf3;stico, hallazgos transoperatorios y evoluci&#xf3;n posoperatoria.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Fueron intervenidos 10 pacientes durante este periodo, con una edad promedio de 64 a&#xf1;os (&#xb1; 8); siete de ellos eran hombres. Los principales s&#xed;ntomas fueron regurgitaci&#xf3;n y disfagia, presentes en ocho y siete pacientes, respectivamente. Los estudios diagn&#xf3;sticos incluyeron endoscopia (nueve pacientes), esofagograma (seis pacientes) y manometr&#xed;a esof&#xe1;gica (tres pacientes). El tratamiento utilizado en todos los casos fue diverticulectom&#xed;a con miotom&#xed;a del cricofar&#xed;ngeo. Las complicaciones incluyeron perforaci&#xf3;n esof&#xe1;gica transoperatoria (un paciente) y f&#xed;stula esof&#xe1;gica (un paciente). Hubo resoluci&#xf3;n de los s&#xed;ntomas en nueve pacientes; el paciente restante amerit&#xf3; nueva miotom&#xed;a seis meses despu&#xe9;s, con una adecuada evoluci&#xf3;n. No hubo ninguna muerte.</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">La diverticulectom&#xed;a con miotom&#xed;a del cricofar&#xed;ngeo es un tratamiento quir&#xfa;rgico seguro para los pacientes con divert&#xed;culo de Zenker.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Zenker&#x2019;s diverticulum represents the most common diverticulum of the esophagus. The standard surgical treatment consists of open cricopharyngeal myotomy with diverticulectomy. In recent years endoscopic treatment has been proposed.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We present the surgical experience of this disease in a referral hospital.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We reviewed the clinical records of all patients submitted to open surgical treatment for Zenker&#x2019;s diverticulum in a 7-year period. The retrieved information included demographic data, clinical manifestations, diagnostic approach, surgery findings and postoperative evolution.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During this period 10 patients were submitted to open surgical treatment; the mean age was 64 (&#xb1; 8) years and seven of them were male. The main complaint was regurgitation and dysphagia that was present in eight and seven patients respectively. Diagnostic studies included endoscopy (nine patients), esophagogram (six patients) and esophageal manometry (three patients). All underwent open cricopharyngeal myotomy with diverticulectomy. Complications included intraoperative esophageal perforation (one patient) and postoperative esophageal fistula (one patient). Resolution of the symptomatology occurred in 9 patients, the other patient required a new myotomy six months later with good results. There was no mortality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cricopharyngeal myotomy with diverticulectomy is a safe option for patients with Zenker&#x2019;s diverticulum.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2018 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosales-Casta&#xf1;eda</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Gastrocirug&#xed;a, Hospital de Especialidades del Centro M&#xe9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Mor&#xe1;n</LastName><ForeName>Grecia C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Servicio de Gastrocirug&#xed;a, Hospital de Especialidades del Centro M&#xe9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Ordaz</LastName><ForeName>Jos&#xe9; L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Servicio de Gastrocirug&#xed;a, Hospital de Especialidades del Centro M&#xe9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Surgical treatment of Zenker&#x2019;s diverticulum.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Cir Cir</MedlineTA><NlmUniqueID>0372736</NlmUniqueID><ISSNLinking>0009-7411</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016672" MajorTopicYN="N">Zenker Diverticulum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Divert&#xed;culo de Zenker</Keyword><Keyword MajorTopicYN="N">Divert&#xed;culo faringoesof&#xe1;gico</Keyword><Keyword MajorTopicYN="N">Divert&#xed;culo faringoesof&#xe1;gico por pulsi&#xf3;n</Keyword><Keyword MajorTopicYN="N">Pharyngoesophageal diverticulum</Keyword><Keyword MajorTopicYN="N">Pharyngoesophageal pulsion diverticula</Keyword><Keyword MajorTopicYN="N">Zenker&#x2019;s diverticulum</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30067720</ArticleId><ArticleId IdType="doi">10.24875/CIRU.M18000054</ArticleId><ArticleId IdType="pii">j86/4/355</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28444098</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2317-6385</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Einstein (Sao Paulo, Brazil)</Title><ISOAbbreviation>Einstein (Sao Paulo)</ISOAbbreviation></Journal><ArticleTitle>The cerebrospinal fluid in multiple sclerosis: far beyond the bands.</ArticleTitle><Pagination><StartPage>100</StartPage><EndPage>104</EndPage><MedlinePgn>100-104</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/S1679-45082017RW3706</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1679-45082017000100100</ELocationID><Abstract><AbstractText>The cerebrospinal fluid analysis has been employed for supporting multiple sclerosis diagnosis and ruling out the differential diagnoses. The most classical findings reflect the inflammatory nature of the disease, including mild pleocytosis, mild protein increase, intrathecal synthesis of immunoglobulin G, and, most typically, the presence of oligoclonal bands. In recent years, new biomarkers have emerged in the context of multiple sclerosis. The search for new biomarkers reflect the need of a better evaluation of disease activity, disease progression, and treatment efficiency. A more refined evaluation of disease and therapy status can contribute to better therapeutic choices, particularly in escalation of therapies. This is very relevant taking into account the availability of a greater number of drugs for multiple sclerosis treatment in recent years. In this review, we critically evaluate the current literature regarding the most important cerebrospinal fluid biomarkers in multiple sclerosis. The determination of biomarkers levels, such as chemokine ligand 13, fetuin A, and mainly light neurofilament has shown promising results in the evaluation of this disease, providing information that along with clinical and neuroimaging data may contribute to better therapeutic decisions. RESUMO A an&#xe1;lise do l&#xed;quido cefalorraquidiano tem sido empregada para avalia&#xe7;&#xe3;o diagn&#xf3;stica da esclerose m&#xfa;ltipla e a exclus&#xe3;o dos diagn&#xf3;sticos diferenciais. Os achados cl&#xe1;ssicos refletem a natureza inflamat&#xf3;ria da doen&#xe7;a, incluindo discreta pleocitose, leve hiperproteinorraquia, aumento da s&#xed;ntese intratecal de imunoglobulina G e, mais tipicamente, a presen&#xe7;a de bandas oligoclonais. Nos &#xfa;ltimos anos, surgiram novos biomarcadores para esclerose m&#xfa;ltipla, e esta busca por marcadores reflete a necessidade de melhor avaliar a atividade e a progress&#xe3;o da doen&#xe7;a, bem como a efic&#xe1;cia terap&#xea;utica. Uma avalia&#xe7;&#xe3;o mais refinada da atividade da doen&#xe7;a e da resposta aos medicamentos pode contribuir para melhores decis&#xf5;es terap&#xea;uticas, particularmente no que se refere &#xe0; troca de medica&#xe7;&#xe3;o. Isto &#xe9; muito importante nos dias de hoje, quando surgem novas op&#xe7;&#xf5;es medicamentosas. Neste artigo de revis&#xe3;o, avaliamos criticamente a literatura atual referente aos novos marcadores liqu&#xf3;ricos na esclerose m&#xfa;ltipla. A mensura&#xe7;&#xe3;o destes marcadores, como a quimiocina CXCL13, fetu&#xed;na A e, principalmente, o neurofilamento de cadeia leve, demonstrou resultados promissores na avalia&#xe7;&#xe3;o da doen&#xe7;a, provendo informa&#xe7;&#xf5;es que, em conjunto com dados cl&#xed;nicos e de neuroimagem, podem contribuir para melhores decis&#xf5;es terap&#xea;uticas.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Domingues</LastName><ForeName>Renan Barros</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Senne Liquor Diagn&#xf3;stico, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Gustavo Bruniera Peres</ForeName><Initials>GBP</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leite</LastName><ForeName>Fernando Brunale Vilela de Moura</ForeName><Initials>FBVM</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tilbery</LastName><ForeName>Charles Peter</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Faculdade de Ci&#xea;ncias M&#xe9;dicas, Santa Casa de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomaz</LastName><ForeName>Rodrigo Barbosa</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Gisele Sampaio</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangueira</LastName><ForeName>Crist&#xf3;v&#xe3;o Luis Pitangueira</ForeName><Initials>CLP</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>Carlos Augusto Senne</ForeName><Initials>CAS</Initials><AffiliationInfo><Affiliation>Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>por</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Einstein (Sao Paulo)</MedlineTA><NlmUniqueID>101281800</NlmUniqueID><ISSNLinking>1679-4508</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004676">Myelin Basic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060749">alpha-2-HS-Glycoprotein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004676" MajorTopicYN="N">Myelin Basic Protein</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060749" MajorTopicYN="N">alpha-2-HS-Glycoprotein</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText>A an&#xe1;lise do l&#xed;quido cefalorraquidiano tem sido empregada para avalia&#xe7;&#xe3;o diagn&#xf3;stica da esclerose m&#xfa;ltipla e a exclus&#xe3;o dos diagn&#xf3;sticos diferenciais. Os achados cl&#xe1;ssicos refletem a natureza inflamat&#xf3;ria da doen&#xe7;a, incluindo discreta pleocitose, leve hiperproteinorraquia, aumento da s&#xed;ntese intratecal de imunoglobulina G e, mais tipicamente, a presen&#xe7;a de bandas oligoclonais. Nos &#xfa;ltimos anos, surgiram novos biomarcadores para esclerose m&#xfa;ltipla, e esta busca por marcadores reflete a necessidade de melhor avaliar a atividade e a progress&#xe3;o da doen&#xe7;a, bem como a efic&#xe1;cia terap&#xea;utica. Uma avalia&#xe7;&#xe3;o mais refinada da atividade da doen&#xe7;a e da resposta aos medicamentos pode contribuir para melhores decis&#xf5;es terap&#xea;uticas, particularmente no que se refere &#xe0; troca de medica&#xe7;&#xe3;o. Isto &#xe9; muito importante nos dias de hoje, quando surgem novas op&#xe7;&#xf5;es medicamentosas. Neste artigo de revis&#xe3;o, avaliamos criticamente a literatura atual referente aos novos marcadores liqu&#xf3;ricos na esclerose m&#xfa;ltipla. A mensura&#xe7;&#xe3;o destes marcadores, como a quimiocina CXCL13, fetu&#xed;na A e, principalmente, o neurofilamento de cadeia leve, demonstrou resultados promissores na avalia&#xe7;&#xe3;o da doen&#xe7;a, provendo informa&#xe7;&#xf5;es que, em conjunto com dados cl&#xed;nicos e de neuroimagem, podem contribuir para melhores decis&#xf5;es terap&#xea;uticas.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28444098</ArticleId><ArticleId IdType="pmc">PMC5433316</ArticleId><ArticleId IdType="doi">10.1590/S1679-45082017RW3706</ArticleId><ArticleId IdType="pii">S1679-45082017000100100</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. 3Brain. 2006;129:606&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">16415308</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol. 2001;14(3):271&#x2013;278. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">11371748</ArticleId></ArticleIdList></Reference><Reference><Citation>Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084507</ArticleId><ArticleId IdType="pubmed">21387374</ArticleId></ArticleIdList></Reference><Reference><Citation>Press EM. A comparative study of cerebrospinal fluid and serum proteins in multiple sclerosis with special reference to the Lange colloidal-gold reaction. Biochem J. 1956;63(3):367&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1216182</ArticleId><ArticleId IdType="pubmed">13341890</ArticleId></ArticleIdList></Reference><Reference><Citation>Harter DH, Yahr MD, Kabat EA. Neurological diseases with elevation of cerebrospinal fluid gamma globulin: a critical review. Trans Am Neurol Assoc. 1962;87:210&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">13953079</ArticleId></ArticleIdList></Reference><Reference><Citation>Tourtellotte WW, Parker JA. Multiple sclerosis: brain immunoglobulin-G and albumin. Nature. 1967;214(5089):683&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">4167421</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowenthal A, Vansande M, Karcher D. The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins. J Neurochem. 1960;6:51&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">13763840</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005;62(6):865&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956157</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72(2):152&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">25531931</ArticleId></ArticleIdList></Reference><Reference><Citation>Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545&#x2013;558. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">26250739</ArticleId></ArticleIdList></Reference><Reference><Citation>Franciotta DM, Grimaldi LM, Martino GV, Piccolo G, Bergamaschi R, Citterio A, et al. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol. 1989;26(6):787&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pubmed">2604386</ArticleId></ArticleIdList></Reference><Reference><Citation>Vladi&#x107; A, Horvat G, Vukadin S, Suci&#x107; Z, Simaga S. Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine. 2002;20(2):86&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">12445803</ArticleId></ArticleIdList></Reference><Reference><Citation>Malmestr&#xf6;m C, Andersson BA, Haghighi S, Lycke J. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles. J Neuroimmunol. 2006;175(1-2):176&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">16626811</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One. 2013;8(4):e61835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3630114</ArticleId><ArticleId IdType="pubmed">23637915</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro D, Galli V, Vitetta F, Simone AM, Bedin R, Del Giovane C, et al. Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: association with oligoclonal IgM bands and prediction of multiple sclerosis diagnosis. J Neuroimmunol. 2015;283:64&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">26004159</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler. 2013;19:1204&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959125</ArticleId><ArticleId IdType="pubmed">23322500</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumani H, Lehmensiek V, Rau D, Guttmann I, Tauscher G, Mogel H, et al. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett. 2009;452(2):214&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">19383442</ArticleId></ArticleIdList></Reference><Reference><Citation>Ottervald J, Franz&#xe9;n B, Nilsson K, Andersson LI, Khademi M, Eriksson B, et al. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J Proteomics. 2010;73(6):1117&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">20093204</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris VK, Donelan N, Yan QJ, Clark K, Touray A, Rammal M, et al. Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis. Mult Scler. 2013;19(11):1462&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">23439582</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8(9):e75091. eCollection 2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64:402&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170011</ArticleId><ArticleId IdType="pubmed">9527161</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni G. Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the &#x2018;Spinal Tap&#x2019;. Mult Scler. 2010;16(3):285&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">20203146</ArticleId></ArticleIdList></Reference><Reference><Citation>Burman J, Zetterberg H, Fransson M, Loskog AS, Raininko R, Fagius J. Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurol Scand. 2014;130(2):81&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571714</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi R. Prognostic factors in multiple sclerosis. Int Rev Neurobiol. 2007;79:423&#x2013;447. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">17531853</ArticleId></ArticleIdList></Reference><Reference><Citation>Oreja-Guevara C, ParadigMS Group Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice. Eur J Neurol. 2015;22(Suppl 2):22&#x2013;27. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">26374510</ArticleId></ArticleIdList></Reference><Reference><Citation>Bielekova B, Komori M, Xu Q, Reich DS, Wu T. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One. 2012;7(11):e48370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511462</ArticleId><ArticleId IdType="pubmed">23226202</ArticleId></ArticleIdList></Reference><Reference><Citation>Romme Christensen J, B&#xf6;rnsen L, Khademi M, Olsson T, Jensen PE, S&#xf8;rensen PS, et al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler. 2013;19(7):877&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">23178691</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzer J. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level - YES. Mult Scler. 2015;21(10):1239&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">25828757</ArticleId></ArticleIdList></Reference><Reference><Citation>Norgren N, Sundstr&#xf6;m P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004;63(9):1586&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534240</ArticleId></ArticleIdList></Reference><Reference><Citation>Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol. 2002;122(1-2):132&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">11777552</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunnarsson M, Malmestr&#xf6;m C, Axelsson M, Sundstr&#xf6;m P, Dahle C, Vrethem M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011;69(1):83&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">21280078</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci. 1995;133(1-2):61&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">8583233</ArticleId></ArticleIdList></Reference><Reference><Citation>Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. 7Brain. 2002;125:1462&#x2013;1473.</Citation><ArticleIdList><ArticleId IdType="pubmed">12076997</ArticleId></ArticleIdList></Reference><Reference><Citation>Malmestr&#xf6;m C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003;61(2):1720&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">14694036</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez MA, Olsson B, Bau L, Matas E, Cobo Calvo &#xc1;, Andreasson U, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015;21(5):550&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4390605</ArticleId><ArticleId IdType="pubmed">25732842</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther. 2009;13(4):225&#x2013;244. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">19712003</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329&#x2013;333. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">26195051</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelsson M, Malmestr&#xf6;m C, Gunnarsson M, Zetterberg H, Sundstr&#xf6;m P, Lycke J, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler. 2014;20(1):43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">23702432</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, Dahlke F, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology. 2015;84(16):1639&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4409586</ArticleId><ArticleId IdType="pubmed">25809304</ArticleId></ArticleIdList></Reference><Reference><Citation>Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol. 2009;16(4):528&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">19220425</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010;67(6):707&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918395</ArticleId><ArticleId IdType="pubmed">20558389</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross AH, Klein RS, Piccio L. Rituximab combination therapy in relapsing multiple sclerosis. Ther Adv Neurol Disord. 2012;5(6):311&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3487534</ArticleId><ArticleId IdType="pubmed">23139702</ArticleId></ArticleIdList></Reference><Reference><Citation>Milo R. Therapeutic strategies targeting B-cells in multiple sclerosis. Autoimmun Rev. 2016;15(7):714&#x2013;718. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">26970489</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27737395</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2175-8239</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Season>Jul-Sep</Season></PubDate></JournalIssue><Title>Jornal brasileiro de nefrologia</Title><ISOAbbreviation>J Bras Nefrol</ISOAbbreviation></Journal><ArticleTitle>Screening for BK virus nephropathy in kidney transplant recipients: comparison of diagnostic tests.</ArticleTitle><Pagination><StartPage>356</StartPage><EndPage>362</EndPage><MedlinePgn>356-362</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5935/0101-2800.20160054</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0101-28002016000300356</ELocationID><Abstract><AbstractText>Urine cytology and qPCR in blood and urine are commonly used to screen renal transplant recipients for polyomavirus-associated nephropathy (PVAN). Few studies, however, have directly compared these two diagnostic tests, in terms of their performance to predict PVAN. This was a systematic review in which adult (&#x2265; 18 years old) renal transplant recipients were studied. A structured Pubmed search was used to identify studies comparing urine cytology and/or qPCR in urine and plasma samples for detecting PVAN with renal biopsy as the gold standard for diagnosis. From 707 potential papers, there were only twelve articles that matched the inclusion criteria and were analyzed in detail. Among 1694 renal transplant recipients that were included in the review, there were 115 (6.8%) patients with presumptive PVAN and 57 (3.4%) PVAN confirmed. In this systematic review, the qPCR in plasma had better performance for PVAN compared to urine cytopathology. Resumo A citologia urin&#xe1;ria e a rea&#xe7;&#xe3;o da cadeia da polimerase em tempo real (qPCR) em amostras de sangue e/ou urina s&#xe3;o comumente utilizados para rastrear nefropatia associada ao polyomavirus (PVAN), em pacientes transplantados renais. Entretanto, poucos estudos comparam diretamente esses testes diagn&#xf3;sticos quanto ao desempenho para predizer esta complica&#xe7;&#xe3;o. Aqui realizamos uma revis&#xe3;o sistem&#xe1;tica na qual foram estudados pacientes transplantados renais adultos (&#x2265; 18 anos). Uma pesquisa estruturada Pubmed foi utilizada para identificar estudos comparando citologia urin&#xe1;ria e/ou qPCR em amostras de urina e plasma para detectar PVAN, utilizando a bi&#xf3;psia renal como padr&#xe3;o-ouro para o diagn&#xf3;stico. Dentre os 707 artigos em potencial, apenas 12 atendiam aos crit&#xe9;rios de inclus&#xe3;o e foram analisados em maior detalhe. Foram inclu&#xed;dos 1694 pacientes transplantados renais, entre os quais 115 (6,8%) classificados com PVAN presuntivo e 57 (3,4%) PVAN confirmado. Nessa revis&#xe3;o sistem&#xe1;tica, o qPCR no plasma tive melhor desempenho para PVAN em compara&#xe7;&#xe3;o com citopatologia urin&#xe1;ria.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Gabriel Godinho</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Universidade Federal de Ci&#xea;ncias da Sa&#xfa;de de Porto Alegre.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poloni</LastName><ForeName>Jose Antonio T</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Universidade Federal de Ci&#xea;ncias da Sa&#xfa;de de Porto Alegre.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Santa Casa de Miseric&#xf3;rdia de Porto Alegre.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotta</LastName><ForeName>Liane N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Universidade Federal de Ci&#xea;ncias da Sa&#xfa;de de Porto Alegre.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razonable</LastName><ForeName>Raymund R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>William J. von Liebig Transplant Center.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Mayo Clinic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasqualotto</LastName><ForeName>Alessandro C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Universidade Federal de Ci&#xea;ncias da Sa&#xfa;de de Porto Alegre.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Santa Casa de Miseric&#xf3;rdia de Porto Alegre.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>por</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>J Bras Nefrol</MedlineTA><NlmUniqueID>9426946</NlmUniqueID><ISSNLinking>0101-2800</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001739" MajorTopicYN="Y">BK Virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025202" MajorTopicYN="N">Molecular Diagnostic Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027601" MajorTopicYN="N">Polyomavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014412" MajorTopicYN="N">Tumor Virus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27737395</ArticleId><ArticleId IdType="doi">10.5935/0101-2800.20160054</ArticleId><ArticleId IdType="pii">S0101-28002016000300356</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27533274</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1518-8345</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><PubDate><Year>2016</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Revista latino-americana de enfermagem</Title><ISOAbbreviation>Rev Lat Am Enfermagem</ISOAbbreviation></Journal><ArticleTitle>Nursing diagnoses in patients with immune-bullous dermatosis.</ArticleTitle><Pagination><StartPage>e2766</StartPage><MedlinePgn>e2766</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2766</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1590/1518-8345.0424.2766</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0104-11692016000100385</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">identify nursing diagnoses in patients with immune-bullous dermatosis.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">a quantitative and descriptive research, carried out in three institutions located in Rio de Janeiro and Mato Grosso do Sul, Brazil, using the Client Assessment Protocol in Dermatology during a nursing consultation. Simple descriptive statistics was used for data analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">14 subjects participated in the study, nine with a diagnosis of pemphigus vulgaris, pemphigus two and three of bullous pemphigoid. The age ranged between 27 and 82 years, predominantly females (11). 14 nursing diagnoses were discussed and identified from a clinical rationale in all study participants, representing the most common human responses in this sample. The application of the Assessment Protocol in Dermatology facilitated the comprehensive assessment, in addition to providing the identification of diagnostics according to the North American Nursing Diagnosis Association International.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">the nursing diagnoses presented confirm the necessity of interdisciplinary work during the care for this clientele. For better description of the phenomena related to the client in question, it is suggested the inclusion of two risk factors related in three diagnoses of this taxonomy. It is worth noting the contribution of the findings for the care, education and research in nursing in dermatology.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">identificar diagn&#xf3;sticos de enfermagem em clientes com dermatoses imunobolhosas.</AbstractText><AbstractText Label="M&#xc9;TODO" NlmCategory="UNASSIGNED">pesquisa quantitativa e descritiva, realizada em tr&#xea;s institui&#xe7;&#xf5;es localizadas no Rio de Janeiro e no Mato Grosso do Sul-Brasil, aplicando o Protocolo de Avalia&#xe7;&#xe3;o do Cliente em Dermatologia, durante consulta de enfermagem. Utilizou-se a estat&#xed;stica descritiva simples para an&#xe1;lise dos dados.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">participaram do estudo 14 sujeitos, nove com diagn&#xf3;stico m&#xe9;dico de p&#xea;nfigo vulgar, dois de foli&#xe1;ceo e tr&#xea;s de penfigoide bolhoso. A idade variou entre 27 e 82 anos, predominando 11 pessoas do sexo feminino. Foram discutidos 14 diagn&#xf3;sticos de enfermagem identificados a partir do racioc&#xed;nio cl&#xed;nico, em todos os participantes do estudo, representando as respostas humanas mais frequentes nesta amostra. A aplica&#xe7;&#xe3;o do Protocolo de Avalia&#xe7;&#xe3;o do Cliente em Dermatologia facilitou a avalia&#xe7;&#xe3;o integral, al&#xe9;m de propiciar a identifica&#xe7;&#xe3;o dos diagn&#xf3;sticos de acordo com a North American Nursing Diagnosis Association International.</AbstractText><AbstractText Label="CONCLUS&#xc3;O" NlmCategory="UNASSIGNED">os diagn&#xf3;sticos de enfermagem apresentados ratificam a necessidade do trabalho interdisciplinar durante atendimento a esta clientela. Para melhor descri&#xe7;&#xe3;o dos fen&#xf4;menos relacionados &#xe0; clientela em quest&#xe3;o, sugere-se a inclus&#xe3;o de dois fatores de risco/relacionados em tr&#xea;s diagn&#xf3;sticos desta taxonomia. Cabe ressaltar a contribui&#xe7;&#xe3;o dos achados para o cuidar/educar/pesquisar em enfermagem em dermatologia.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">identificar los diagn&#xf3;sticos de enfermer&#xed;a en pacientes con inmuno dermatosis ampollosa.</AbstractText><AbstractText Label="M&#xc9;TODO" NlmCategory="UNASSIGNED">investigaci&#xf3;n cuantitativa y descriptiva, realizada en tres instituciones ubicadas en R&#xed;o de Janeiro y Mato Grosso do Sul, Brasil, utilizando el Protocolo de Evaluaci&#xf3;n del Cliente en Dermatolog&#xed;a en la consulta de enfermer&#xed;a. Se utiliz&#xf3; estad&#xed;stica descriptiva simples para el an&#xe1;lisis de datos.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">14 sujetos participaron en el estudio, nueve con diagn&#xf3;stico de p&#xe9;nfigo vulgar, dos de p&#xe9;nfigo foli&#xe1;ceo y tres de penfigoide ampolloso. La edad oscil&#xf3; entre 27 y 82 a&#xf1;os, predominio femenino con 11 mujeres. Se discutieron 14 diagn&#xf3;sticos de enfermer&#xed;a identificados desde el razonamiento cl&#xed;nico, en todos los participantes en el estudio, que representa las respuestas humanas m&#xe1;s comunes en esta muestra. La aplicaci&#xf3;n del Protocolo de Evaluaci&#xf3;n de Dermatolog&#xed;a facilit&#xf3; la evaluaci&#xf3;n global, adem&#xe1;s de proporcionar la identificaci&#xf3;n de los diagn&#xf3;sticos de acuerdo con la North American Nursing Diagnosis Association International.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N" NlmCategory="UNASSIGNED">los diagn&#xf3;sticos de enfermer&#xed;a presentados confirman la necesidad del trabajo interdisciplinario en el servicio a estos clientes. Para una mejor descripci&#xf3;n de los fen&#xf3;menos relacionados con los clientes en cuesti&#xf3;n, se sugiere la inclusi&#xf3;n de dos factores de riesgo/relacionados en tres diagn&#xf3;sticos de esta taxonom&#xed;a. Vale la pena se&#xf1;alar la contribuci&#xf3;n de los hallazgos para el cuidado/educaci&#xf3;n/investigaci&#xf3;n en enfermer&#xed;a en dermatolog&#xed;a.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brand&#xe3;o</LastName><ForeName>Euzeli da Silva</ForeName><Initials>Eda S</Initials><AffiliationInfo><Affiliation>PhD, Adjunct Professor, Escola de Enfermagem Aurora de Afonso Costa, Universidade Federal Fluminense, Niter&#xf3;i, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Iraci Dos</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>PhD, Full Professor, Faculdade de Enfermagem, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanzillotti</LastName><ForeName>Regina Serr&#xe3;o</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>PhD, Full Professor, Instituto de Matem&#xe1;tica e Estat&#xed;stica, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Adriano Menis</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>PhD, Adjunct Professor, Universidade Federal do Mato Grosso do Sul, Tr&#xea;s Lagoas, MS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamba</LastName><ForeName>M&#xf4;nica Antar</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>PhD, Associate Professor, Escola Paulista de Enfermagem, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azulay-Abulafia</LastName><ForeName>Luna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>PhD, Adjunct Professor, Faculdade de Medicina, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>por</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Rev Lat Am Enfermagem</MedlineTA><NlmUniqueID>9420934</NlmUniqueID><ISSNLinking>0104-1169</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009733" MajorTopicYN="Y">Nursing Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012872" MajorTopicYN="N">Skin Diseases, Vesiculobullous</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27533274</ArticleId><ArticleId IdType="pmc">PMC4996093</ArticleId><ArticleId IdType="doi">10.1590/1518-8345.0424.2766</ArticleId><ArticleId IdType="pii">S0104-11692016000100385</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brand&#xe3;o ES, Santos I. Evidences related to the care of people with pemphigus vulgaris: a
challenge to nursing. Online Braz J Nurs. 2013;12(1):162&#x2013;177. http://www.objnursing.uff.br/index.php/nursing/article/view/3674/html</Citation></Reference><Reference><Citation>Brand&#xe3;o ES, Santos I, Carvalho MR, Pereira SK. Nursing care evolution to the client with pemphigus integrative literature review. Rev Enferm UERJ. 2011;19(3):479&#x2013;484.</Citation></Reference><Reference><Citation>Pokomy ME. Alligood MR, Marriner-Tomey A. Nursing theorists and their work. USA: Mosby Elsevier; 2010. Nursing theorists of historical significance; pp. 54&#x2013;68.</Citation></Reference><Reference><Citation>Garcia TR, N&#xf3;brega MM. Nursing process from theory to the practice of care and research. Esc Anna Nery. 2009;13(1):816&#x2013;818.</Citation></Reference><Reference><Citation>Cunha PR, Barraviera SR. Autoimmune bullous dermatoses. An Bras Dermatol. 2009;84(2):111&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">19503978</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira CR, Zanetti ML, Pereira MC. Nursing diagnoses in people with diabetes mellitus according to Orems'theory of self-care. Acta Paul Enferm. 2009;22(4):385&#x2013;389.</Citation></Reference><Reference><Citation>Santos APS, Silva MLC, Souza NL, Mota GM, Fran&#xe7;a DF. Nursing diagnoses of new borns with sepsis in a neonatal intensive care unit Rev. Latino-Am. Enfermagem. 2014;22(2):255&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4292594</ArticleId><ArticleId IdType="pubmed">26107833</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldanha EA, Medeiros ABA, Fraz&#xe3;o CMFQ, Silva VM, Lopes MVO, Lira ALBC. Nursing diagnoses in patients undergoing prostatectomy identification of the significance of its componentes. Rev Bras Enferm. 2014;67(3):430&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">25054706</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalcante AMRZ, Brunori EHFR, Lopes CT, Silva ABV, Herdman TH. Nursing diagnoses and interventions for a child after cardiac surgery in an intensive care unit. Rev Bras Enferm. 2015;68(1):155&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">25946508</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho MO, Jorge MSB. Technology of relations as device of humanized attendance in basic attention to health in the perspective of access, sheltering and attachment. Ci&#xea;nc Sa&#xfa;de Coletiva. 2009;14:1523&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">19750362</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos I, Caldas CP, Gauthier J, Erdmann AL, Figueiredo NM. Caring for the whole person the contributions of aesthetics/sociopoetics perspectives to the field of nursing. Rev Enferm UERJ. 2012;20(1):4&#x2013;9.</Citation></Reference><Reference><Citation>Kletemberg DF, Siqueira MT, Mantovani MF, Padilha MI, Amante LN, Anders JC. The nursing process and the law of professional exercise. Rev Bras Enferm. 2010;63(1):26&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">20339751</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos I, Brand&#xe3;o ES, Clos AC. Dermatology nursing sensitive listening skills and technology for actingin skincare. Rev Enferm UERJ. 2009;17(1):124&#x2013;129.</Citation></Reference><Reference><Citation>Brand&#xe3;o ES, Santos I, Lanzillotti RS. Validation of an instrument to assess patients with skin conditions. Acta Paul Enferm. 2013;26(5):460&#x2013;466.</Citation></Reference><Reference><Citation>Merhy EE, Franco TB. Por uma composi&#xe7;&#xe3;o t&#xe9;cnica do trabalho centrada no campo relacional e nas tecnologias leves. Sa&#xfa;de em Debate. 2003;27(65):316&#x2013;323.</Citation></Reference><Reference><Citation>NANDA International . Diagn&#xf3;sticos de Enfermagem da NANDA: defini&#xe7;&#xf5;es e classifica&#xe7;&#xe3;o 2012-2014. Porto Alegre: Artmed; 2013.</Citation></Reference><Reference><Citation>Minist&#xe9;rio da Sa&#xfa;de . Conselho Nacional de Sa&#xfa;de, Diretrizes e normas regulamentadoras de pesquisa envolvendo seres humanos. Resolu&#xe7;&#xe3;o n. 466, de 12 de dezembro de 2012. Bras&#xed;lia(DF): Minist&#xe9;rio da Sa&#xfa;de; 2012.</Citation></Reference><Reference><Citation>Souza SR, Azulay-Abulafia L, Nascimento LV. Validation of the Commitment Index of Skinand Mucous Membranes in Pemphigus Vulgaris for the clinical evaluation of patients with pemphigus vulgaris. An Bras Dermatol. 2011;86(2):284&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">21603812</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>